Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough

SIMPLE SUMMARY: The treatment scenario of metastatic renal cell carcinoma has drastically changed in recent years, with the advent of immunotherapy. Since 2015 immune-checkpoint inhibitors, either alone or in combination with other compounds, are constantly enriching the treatment scenario, with a d...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancers (Basel)
Egile Nagusiak: Mollica, Veronica, Brocchi, Stefano, Dall’Olio, Filippo Gustavo, Marcolin, Laura, Paccapelo, Alexandro, Santoni, Matteo, Rizzo, Alessandro, Montironi, Rodolfo, Golfieri, Rita, Massari, Francesco, Ardizzoni, Andrea
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI 2021
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8304626/
https://ncbi.nlm.nih.gov/pubmed/34298702
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13143492
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak